Moderna (MRNA) Requests to Expand Conditional Marketing Authorization for its COVID-19 Vaccine in the EU to Include Children Ages 6-11 Years

Wolfe Research Starts Moderna (MRNA) at Outperform

November 8, 2021 5:53 PM EST

Wolfe Research analyst Andrew Galler initiates coverage on Moderna (NASDAQ: MRNA) with a Outperform rating and a price target of $304.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $236.99 yesterday.

... More

Vaccine Stocks on Watch on Positive News on Regeneron's Anti-Viral

November 8, 2021 7:11 AM EST

Vaccine stocks on watch following news a single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1.

BioNTech SE (NASDAQ: BNTX) +4.3%Moderna (NASDAQ: MRNA) -3.2%Novavax (NASDAQ: NVAX) -0.9%Pfizer (NYSE: PFE) -0.4%
... More

Popular stocks with increasing volume: PFE F MRNA PTON QCOM ABNB INTC DKNG AAL BBBY

November 8, 2021 3:56 AM EST

Popular stocks with increasing volume: PFE F MRNA PTON QCOM ABNB INTC DKNG AAL BBBY

... More

Moderna (MRNA) Hits Low, Down 25% on Session

November 5, 2021 12:51 PM EDT

Moderna (NASDAQ: MRNA) Hits Low, Down 25% on Session

... More

Increasing unusual option volume: BE BBBY RRD QCOM FROG MRNA WKHS LCID RWLK ALZN OTRK YELL YELP RBAC

November 5, 2021 11:03 AM EDT

Increasing unusual option volume: BE BBBY RRD QCOM FROG MRNA WKHS LCID RWLK

... More

Pre-Open Stock Movers 11/5: (BIGC) (EXPE) (PFE) Higher; (PTON) (MRNA) (MRK) Lower (more...)

November 5, 2021 9:25 AM EDT

Pre-Open Stock Movers:

Peloton (NASDAQ: PTON) 33% LOWER; reported Q1 EPS of ($1.25), $0.18 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $805.2 million versus the consensus estimate of $810.76 million. Peloton sees Q2 2022 revenue of $1.1-1.2 billion, versus the consensus of $1.51 billion. Peloton sees FY2022 revenue of $4.4-4.8 billion, versus the consensus of $5.4 billion.

Moderna, Inc. (NASDAQ: MRNA) 14.7% LOWER; falls on positive data from Pfizer's COVID-19 antiviral drug.

BigCommerce (NASDAQ:... More

Moderna (MRNA) PT Lowered to $325 at Jefferies

November 5, 2021 8:24 AM EDT

Jefferies analyst Michael Yee lowered the price target on Moderna (NASDAQ: MRNA) to $325.00 (from $375.00) while maintaining a Hold rating.

The analyst commented, "In our investor conversations, there is a debate around shifting of 2021 (down by $5B) and 2022 guidance (up by $5B)... More

Moderna (MRNA) Falls 5% Following Positive Pfizer COVID-19 Oral Antiviral Treatment Data

November 5, 2021 7:01 AM EDT

Moderna (NASDAQ: MRNA) falls 5% following positive Pfizer COVID-19 Oral Antiviral Treatment Data.

... More

Moderna (MRNA) PT Lowered to $404 at Barclays

November 5, 2021 4:51 AM EDT

Barclays analyst Gena Wang lowered the price target on Moderna (NASDAQ: MRNA) to $404.00 (from $463.00) while maintaining a Overweight rating.... More

Moderna (MRNA) PT Lowered to $395 at Goldman Sachs

November 5, 2021 4:24 AM EDT

Goldman Sachs analyst Salveen Richter lowered the price target on Moderna (NASDAQ: MRNA) to $395.00 (from $461.00) while maintaining a Buy rating.... More

Moderna (MRNA ) PT Lowered to $313 at Morgan Stanley

November 5, 2021 3:44 AM EDT

Morgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA ) to $313.00 (from $337.00) while maintaining a Equalweight rating.... More